INTRODUCTION {#s1}
============

The organization of the genome into functional domains ensures that the appropriate temporal and tissue-specific patterns of gene expression are achieved. Within a certain domain, expression patterns are determined by the interaction of several regulatory elements, including promoters, enhancers and insulators. Epigenetic modifications, such as DNA methylation, can modify the interactions between genes and their regulatory sequences. In the case of imprinted genes, two alleles with parental-specific epigenetic modifications coexist and result in distinct allelic expression patterns.

At the *H19*/*Igf2* locus, common enhancers activate *H19* on the maternal chromosome and *Igf2* on the paternal chromosome ([@DDN200C1]--[@DDN200C4]). The allele-specific pattern is due to the epigenetic switch of an insulator/transcriptional activator lying upstream of *H19* ([@DDN200C5]), designated as the differentially methylated domain (DMD). On the maternal chromosome, this region binds to CTCF ([@DDN200C6]--[@DDN200C10]), with two outcomes: *H19* expression is initiated in the blastocyst ([@DDN200C11],[@DDN200C12]) and the enhancers driving this transcription are blocked from activating *Igf2* promoters on that chromosome. On the paternal chromosome, the region is hypermethylated ([@DDN200C11],[@DDN200C13]), CTCF does not bind and the enhancers can access the *Igf2* promoters to drive transcription paternally. Subsequent methylation of the *H19* promoter inhibits its expression.

We have developed several mouse models to investigate the requirement of the DMD for proper imprinting regulation and to determine the role of CTCF binding to the DMD by generating loss of function and gain of function mutations (Fig. [1](#DDN200F1){ref-type="fig"}). The *H19*^*Δ3.8--5′H19*^ line has 3.8 kb upstream of the *H19* gene encompassing the DMD deleted ([@DDN200C14]), resulting in biallelic *Igf2* expression when the allele is inherited maternally. In the *H19*^DMD-ΔR^ mutation, only the CTCF binding sites within the DMD have been deleted ([@DDN200C12]). We have shown that in this line, the maternal insulator cannot be established, and that transcriptional initiation of *H19* is delayed. In the *H19*^*9CG-DMD*^ line, 9 CG dinucleotides within the CTCF binding sites have been mutagenized ([@DDN200C10]), and although methylation is established when inherited paternally, CTCF is able to bind to the DMD and establish an ectopic enhancer-blocker, resulting in decreased levels of *Igf2*.

![Representation of the *Igf2/H19* loci and the mutants used in this study, including their methylation and expression patterns. Arrows represent expression, hatched arrows represent reduced levels of expression and filled circles indicate DNA methylation. The *H19*^Δ3.8\ kb-5′H19^ allele has a 3.8 kb deletion that removes the DMD. The *H19*^DMD-ΔR^ allele lacks the four core binding sites for CTCF within the DMD. The *H19*^DMD-9CG^ allele replaces 9CGs within the CTCF binding sites of the DMD.](ddn20001){#DDN200F1}

These experiments highlighted the critical importance of CTCF in the control of expression patterns in the *H19*/*Igf2* locus. Studies at the β-globin locus had suggested that CTCF functions by organizing the three-dimensional structure of the locus, inducing the formation of chromatin loops that establish independent domains of transcriptional activity ([@DDN200C15]). At the *H19*/*Igf2* locus, recent studies have investigated different aspects of the interactions between the regulatory elements ([@DDN200C16]--[@DDN200C18]). Some discrepancies have emerged from these reports. Kurukuti *et al*. suggest that on the maternal chromosome, the insulator interacts with a matrix attachment region and a differentially methylated region at the *Igf2* locus to generate a tight loop around the maternal *Igf2* gene, which results in silencing. Yoon *et al*. report that the DMD forms direct associations with the enhancers and the inactive *Igf2* promoters. Whereas the former studies indicate that the insulator forms a physical impediment to activation of *Igf2*, the latter posits that enhancer-blocking is the result of direct interaction with the enhancers and inactive promoter, generating a transcriptionally unproductive association. The findings on the paternal-specific associations also conflict. Kurukuti *et al*. maintain that both *H19* and *Igf2* are accessible to interaction with the enhancers on the paternal chromosome, whereas Yoon *et al*. only tested association between the enhancers and the active *Igf2* promoter.

While each of these studies yielded insight into the organization of the *H19*/*Igf2* locus, the discrepancies in their results have left some unanswered questions with respect to the mechanisms of enhancer-blocking and transcriptional activation. We wished to carry out a detailed scan across the entire *H19*/*Igf2* region to determine the parental-specific chromatin loop organization associated with the active transcriptional status as well as repression mediated by enhancer-blocking activity or methylation. We focused on the behavior of the endodermal enhancers in neonatal liver, and our array of mouse models provided an opportunity to compare wild-type chromosomes with alleles containing a variety of mutations in the CTCF sites. We used Chromosome Conformation Capture (3C) ([@DDN200C19]) in order to identify the long-range interactions between the promoters, the endodermal enhancers and the DMD.

In the wild-type mouse, we find that on the maternal chromosome, the enhancers make contacts throughout the region including the *H19* coding unit and promoter, up to the DMD. On the paternal chromosome, the enhancers are engaged exclusively by the *Igf2* promoter and have no detectable interaction with the *H19* gene. Upon deletion of the maternal DMD, we find that the maternal enhancers interact in an unrestricted way with both *H19* and *Igf2* regions. This suggests that the DMD is required to confine the interaction of enhancers to the *H19* region. Similarly, when the CTCF binding sites are absent on the maternal allele, the enhancers have unlimited access to the whole region, showing that CTCF is necessary for enhancer-blocking activity. When the *H19*^DMD-9CG^ allele is inherited paternally, the enhancers are mainly found at the *H19* region. Physical presence beyond the paternally established insulator is limited, indicating that CTCF binding in the mutant DMD restricts the access of the enhancers to the *Igf2* promoter.

RESULTS {#s2}
=======

We used 3C technology to investigate the interactions that occur between the endodermal enhancers and the *H19* and *Igf2* genes in the neonatal liver. The 3C assay employs cross-linking, restriction digestion, ligation and PCR amplification of ligated fragments to determine the frequency of physical contacts between different regions along the chromosome ([@DDN200C19]). In our experimental approach, the samples were generated by crosses between wild-type or mutant C57BL/6J and B6(CAST7) mice. The alleles assayed are depicted in Figure [1](#DDN200F1){ref-type="fig"}. We analyzed neonatal livers, the tissue with the highest expression of *H19* and *Igf2*. Nuclei were treated with formaldehyde to crosslink proteins that mediate association between the endodermal enhancers that lie downstream of *H19* and other regulatory elements. The crosslinked chromatin was digested with *Psu*I, separating fragments that contained the regulatory elements of the *H19*/*Igf2* locus. *Psu*I digestion generated appropriately spaced fragments that fully contained the regulatory elements of the *H19*/*Igf2* locus. There was no allelic or regional bias in the digestion pattern (data not shown). DNA ligase was added to link the sequences that co-localized in the nucleus, independently of their location along the chromosome. After reversing the crosslinks and removing the proteins, DNA sequences associated with the endodermal enhancers were identified by PCR. In each reaction, the PCR product was the correct size. Restriction fragment length polymorphisms between the strains used allowed us to distinguish the parental origin of the ligation products. None of the products were observed in the absence of ligation of the chromatin. At least two PCRs were carried out for each of the two independent 3C experiments. Representative results are shown throughout.

Allele-specific chromosome looping at the *H19*/*Igf2* locus {#s2a}
------------------------------------------------------------

In the wild-type mouse, *H19* is expressed from the maternal allele, whereas *Igf2* is active on the paternal chromosome. Our results from the 3C assay were identical for reciprocal crosses of C57BL/6J × B6(CAST7) and indicated that the maternal enhancers contacted the entire *H19* region, including the promoter, correlating with the active transcriptional status of the maternal *H19* gene (Fig. [2](#DDN200F2){ref-type="fig"}, see maternal bands in panels 5--7). However, on the maternal chromosome, the enhancers were not found beyond the DMD. This suggests that the presence of an insulator assembled in this region on the maternal copy physically bars the enhancers from moving upstream.

![Analysis of long-range interactions at the *H19* locus. (**A**) Schematic of the *H19* locus, including the position of the coding sequence (black box), the differentially methylated domain (hatched box, DMD) and the endodermal enhancers (circles, EE). Vertical bars indicate *Psu*I restriction sites, numbers beneath the sites are the distance relative to the *H19* transcriptional start site, and the resulting digestion fragments are numbered ([@DDN200C1]--[@DDN200C9]). Arrowheads represent the location of PCR primers for 3C analysis. The white arrowhead is the reverse primer for all reactions, which test for ligation of fragments 1--9 to the EE fragment. An asterisk indicates a restriction polymorphism that distinguishes C57BL/6J and B6(CAST7) alleles. Samples were from wild-type progeny of C57BL/6J and B6(CAST7) mice (B × C, C × B), with the female indicated first. (**B**) Representative gel image of 3C analysis at the *H19* locus. Shown are the 3C PCR products: D, digested with *Nla*III, which distinguishes paternal (P) from maternal alleles (M); 3C, non-digested PCR product; -L, no ligase control; +, positive control. The endodermal enhancers on the maternal chromosome associate with fragments in the *H19* region up to the DMD, beyond which only fragments from the paternal chromosome are observed.](ddn20002){#DDN200F2}

Whereas the enhancers were absent from the regions upstream of the DMD on the maternal chromosome, they interacted freely with those regions on the paternal allele (Fig. [2](#DDN200F2){ref-type="fig"}, see paternal bands in panels 1--4). This suggests that upon inactivation of the DMD by methylation, the enhancers are no longer restricted to the *H19* region.

The paternally expressed *Igf2* gene has four promoters and exhibits differential promoter usage throughout development ([@DDN200C20]). Restriction digestion with *Psu*I yields three fragments containing *Igf2* promoter sequences: fragment 10 contains the placental promoter, fragment 13 contains promoter 1 and fragment 14 contains promoters 2 and 3 (Fig. [3](#DDN200F3){ref-type="fig"}A). In the 3C assay, the paternal enhancers associated with the three fragments containing the *Igf2* promoters (Fig. [3](#DDN200F3){ref-type="fig"}, see paternal bands in panels 10, 13 and 14), with the strongest signal at promoters 2 and 3. In fact, promoter 3 is the main origin of transcripts arising in neonatal liver. The signal at the placental promoter is either very weak or absent, consistent with the lack of expression from this promoter in liver. These results confirm that enhancer--promoter associations are required to achieve RNA expression. Interestingly, no physical proximity between the enhancers and the *H19* promoter was detected on the paternal chromosome (Fig. [2](#DDN200F2){ref-type="fig"}, panels 5--7), suggesting that the enhancers are somehow excluded from the region, possibly due to the hypermethylation on this allele.

![Analysis of long-range interactions between the endodermal enhancers and the *Igf2* locus. (**A**) Schematic of the *Igf2* locus, showing the exons (black boxes) and the differentially methylated regions (hatched boxes, DMR~o~, DMR~1~, DMR~2~). Vertical bars indicate *Psu*I restriction sites, numbers beneath the sites are the distance relative to the *Igf2* exon 1 and the resulting digestion fragments from the region contacted by the endodermal enhancers are numbered ([@DDN200C10]--[@DDN200C14]). Downstream fragments showed no contact with the endodermal enhancers (data not shown). Arrowheads represent the location of PCR primers for 3C analysis. The white arrowhead at the endodermal enhancers downstream of *H19* is the reverse primer for all reactions, which test for ligation of fragments 10--14 to the EE fragment. An asterisk indicates a restriction polymorphism that distinguishes C57BL/6J and B6(CAST7) alleles. Samples were from wild-type progeny of C57BL/6J and B6(CAST7) mice (B × C, C × B), with the female indicated first. (**B**) Representative gel image of 3C analysis of interactions of the endodermal enhancers with the *Igf2* locus. Shown are the 3C PCR products: D, digested with *Hae*III, which distinguishes paternal (P) from maternal alleles (M), 3C, non-digested PCR product; -L, no ligase control; +, positive control. The endodermal enhancers on the maternal chromosome associate predominantly with fragments originating in the paternal chromosome.](ddn20003){#DDN200F3}

The DMD is required for appropriate maternal chromosome conformation {#s2b}
--------------------------------------------------------------------

To prove that the restricted interaction of the endodermal enhancers on the maternal chromosome is dependent on the presence of the insulator, we used an allele that removed the DMD. When the *H19*^Δ3.8\ kb-5′H19^ mutation is inherited maternally, the normally silent *Igf2* gene is activated, resulting in biallelic expression ([@DDN200C14]). In contrast to behavior of the wild-type maternal chromosome, the analysis of the maternally inherited *H19*^Δ3.8\ kb-5′H19^ allele showed contact between the endodermal enhancers and the regions upstream of the DMD (Fig. [4](#DDN200F4){ref-type="fig"}A, see maternal and paternal signals in panels 1--4).

![The *H19* DMD is required to prevent interactions between the maternal endodermal enhancers and the *Igf2* promoters. The 3C analysis was carried out on samples from a *H19*^Δ3.8\ kb-5′H19^ × B6(CAST7) cross. (**A)** Top, schematic of the *H19*^Δ3.8\ kb-5′H19^ allele (see Fig. [2](#DDN200F2){ref-type="fig"} for details), with 3.8 kb upstream of the *H19* promoter removed. Bottom, representative gel image of 3C PCR products: D, digested with *Nla*III, which distinguishes paternal (P) from maternal (M) alleles; 3C, non-digested PCR product; -L, no ligase control; +, positive control. When the *H19*^Δ3.8\ kb-5′H19^ allele is inherited maternally, the endodermal enhancers on the maternal chromosome interact with the whole *H19* region. (**B**) Top, schematic of the *Igf2* locus (see Fig. [3](#DDN200F3){ref-type="fig"} for details). Bottom, representative gel image of 3C PCR products digested with *Hae*III, which distinguishes paternal (P) from maternal (M) alleles.](ddn20004){#DDN200F4}

In the absence of the DMD, the enhancers occupy *Igf2* promoters 1--3 on both maternal and paternal chromosomes (Fig. [4](#DDN200F4){ref-type="fig"}B, see maternal and paternal bands in panels 13 and 14). These observations establish that the DMD is required for the appropriate chromosome conformation that restricts the maternal enhancers to the *H19* promoter.

CTCF binding sites are essential in organizing the chromosome domains {#s2c}
---------------------------------------------------------------------

While the previous experiment showed that the DMD was required for appropriate interactions of the locus, it remained to be determined whether it was the CTCF binding sites within the region that were mediating these contacts. The *H19*^DMD-ΔR^ mutation lacks the four core binding sites of CTCF in the DMD region. Mice inheriting the mutation maternally exhibit biallelic *Igf2* expression and a delay in the onset of *H19* expression ([@DDN200C12]). The 3C analysis showed that upon maternal inheritance of the *H19*^DMD-ΔR^ allele, the endodermal enhancers were not confined to the *H19* region, but rather displayed physical association throughout the *H19* locus (Fig. [5](#DDN200F5){ref-type="fig"}A, see maternal and paternal bands in panels 1--3). This suggests that the binding of CTCF to its cognate sites is required to block the enhancers from associating with regions beyond the DMD.

![The CTCF sites are necessary for the enhancer-blocking activity of the DMD. The 3C analysis was carried out on samples from a *H19*^DMD-ΔR^ × B6(CAST7) cross. (**A**) Top, schematic of the *H19*^DMD-ΔR^ allele, in which the CTCF sites in the DMD have been deleted (see Fig. [2](#DDN200F2){ref-type="fig"} for details). Bottom, representative gel image of 3C PCR products: D, digested with *Nla*III, which distinguishes paternal (P) from maternal (M) alleles; 3C, non-digested PCR product; -L, no ligase control; +, positive control. (**B**) Top, schematic of the *Igf2* locus (see Fig. [3](#DDN200F3){ref-type="fig"} for details). Bottom, representative gel image of 3C PCR products digested with *Hae*III, which distinguishes paternal (P) from maternal (M) alleles.](ddn20005){#DDN200F5}

Consistent with the biallelic expression of *Igf2*, the enhancers contact the *Igf2* promoters equally on both parental chromosomes (Fig. [5](#DDN200F5){ref-type="fig"}B, see maternal and paternal bands in panels 13 and 14). This behavior is equivalent to that of the *H19*^Δ3.8kb-5′H19^ allele, in which the DMD has been completely deleted. Thus, binding of CTCF in the DMD is necessary to abolish maternal associations between the enhancers and the *Igf2* promoters.

Methylation diminishes the strength of the insulator function {#s2d}
-------------------------------------------------------------

Binding of CTCF to its recognition sites within the DMD is methylation-sensitive. Therefore, the paternally hypermethylated DMD does not exhibit enhancer-blocking activity. The *H19*^DMD-9CG^ mutation is a parent-of-origin-specific gain-of-function mutation, in which an insulator is assembled on the paternal DMD ([@DDN200C10]). As a result, paternal *Igf2* mRNA levels are reduced, and the mice display a growth restriction phenotype. Furthermore, the normally silent paternal allele of *H19* is activated. The 3C analysis showed that the endodermal enhancers interacted with the *H19* promoter biallelically, consistent with the biallelic expression of *H19* in this mutant (Fig. [6](#DDN200F6){ref-type="fig"}A, panels 5--7). Beyond the DMD, only very faint signals were observed, indicating reduced paternal interactions (Fig. [6](#DDN200F6){ref-type="fig"}A, panels 1--4). Furthermore, the strength of interaction between the enhancer and the *Igf2* promoters was diminished or undetectable (Fig. [6](#DDN200F6){ref-type="fig"}B, panels 13 and 14). These results indicate that the ectopic insulator established on the paternal DMD is partially successful in restricting the enhancers to the *H19* region.

![The *H19*^DMD-9CG^ insulator is weaker than the wild-type one. The 3C analysis was carried out on samples from a B6(CAST7) × *H19*^DMD-9CG^ cross. (**A**) Top, schematic of the *H19*^DMD-9CG^ allele, in which nine CpGs in the CTCF binding sites in the DMD have been replaced with alternative nucleotides (see Fig. [2](#DDN200F2){ref-type="fig"} for details). Bottom, representative gel image of 3C PCR products: D, digested with *Nla*III, which distinguishes paternal (P) from maternal (M) alleles; 3C, non-digested PCR product; -L, no ligase control; +, positive control. (**B**) Top, schematic of the *Igf2* locus (see Fig. [3](#DDN200F3){ref-type="fig"} for details). Bottom, representative gel image of 3C PCR products digested with *Hae*III, which distinguishes paternal (P) from maternal (M) alleles.](ddn20006){#DDN200F6}

DISCUSSION {#s3}
==========

Imprinted gene expression is unique in that two disparately regulated alleles co-exist in the same nuclear environment. Moreover, the epigenetic status of the alleles depends on their parental origin. The imprinted *H19* /*Igf2* locus has been the focus of extensive studies. Differential DNA methylation and allele-specific chromatin modifications have been described in detail ([@DDN200C13],[@DDN200C21]--[@DDN200C23]). Several targeted mutations in the mouse have helped delimit and elucidate the function of important *cis*-acting elements ([@DDN200C5],[@DDN200C6],[@DDN200C10],[@DDN200C24]--[@DDN200C26]). The model that has emerged and is strongly supported by these studies proposes that on the maternal chromosome, a CTCF-mediated enhancer-blocker is assembled at a region upstream of *H19*, and as a result, enhancers lying downstream of *H19* cannot access the *Igf2* promoters and thus activate the *H19* promoter. On the paternal chromosome, methylation inherited from the male gamete inhibits binding of CTCF, enabling the interaction between the enhancers and the *Igf2* gene.

The development of 3C technology has allowed us to detect physical interactions between distant regions of the chromosome, supporting a model in which intervening DNA is looped out to accommodate the functional association between *cis*-acting regulatory elements ([@DDN200C19]). We have used 3C at the *H19*/*Igf2* locus to examine the interactions between the endodermal enhancers, the *H19* and *Igf2* promoters, and the DMD on each of the parental alleles. In the 3C assay, predicted interactions between regulatory elements are systematically tested by examining the relative frequency of physical proximity between them. Although physical proximity does not necessarily translate into functional significance, in conjunction with the expression patterns and using mutations in the regulatory elements comparatively, the association of DNA sequences can yield insight into molecular mechanisms of transcriptional activation and repression.

We have analyzed wild-type mice and three mouse models in which mutations affecting the insulator activity have been targeted to the DMD. Our findings are summarized in Figure [7](#DDN200F7){ref-type="fig"}. We find that in the wild-type mouse, interactions between the endodermal enhancers and the *H19* and *Igf2* promoters reflect the imprinted expression pattern, i.e. they occur in an allele-specific way. On the maternal chromosome, the enhancers contact the active *H19* promoter, whereas on the paternal chromosome, the enhancers associate with the paternally expressed *Igf2* promoters. Furthermore, in all of our targeted mouse models, biallelic expression correlates with enhancer localization at both paternal and maternal promoters. In the paternally inherited *H19*^DMD-9CG^ allele, CTCF is able to bind its cognate sites within the DMD. Methylation is established normally in the germ line, but is partially lost by the blastocyst stage, possibly because the presence of CTCF impedes access of the maintenance DNA methyltransferase. As a result, *H19* is expressed from the normally silent paternal allele at 35% the levels of the maternal allele in neonatal liver. Concordantly, our 3C results show the interactions of the endodermal enhancers with both the maternal and paternal *H19* promoters. In the *H19*^Δ3.8kb-5′H19^ and *H19*^DMD-ΔR^ mutants, both of which display biallelic *Igf2* expression, the enhancers are in proximity to both maternal and paternal *Igf2* promoters. Thus, direct physical contact between the enhancers and the promoters correlate with the gene expression, supporting the view that the interactions are functional. This is consistent with findings in a previous report ([@DDN200C18]).

![Summary of the parental-specific interactions of the endodermal enhancers along the *H19*/*Igf2* locus in neonatal livers of wild-type and targeted mice. Mutations are described in the legend of Figure [1](#DDN200F1){ref-type="fig"} and detailed in the text. Arrows represent expression, hatched arrows represent low levels of expression, and filled circles indicate methylation. Stars represent regions of contact, as detected by the 3C assay.](ddn20007){#DDN200F7}

A major finding of this study is that the enhancer-blocking activity of insulators does not allow physical interactions to occur between the enhancers and regions beyond the insulator. Specifically, in the wild-type mouse, the presence of the DMD on the maternal chromosome restricts the association of the endodermal enhancers to the *H19* promoter and gene body. No contacts are detected beyond the DMD. In contrast, in the mutants in which the DMD is either removed (*H19*^Δ3.8kb-5′H19^) or inactivated by deletion of the CTCF binding sites (*H19*^DMD-ΔR^), the enhancers are capable of forming associations with the regions upstream of the DMD. Indeed, on the wild-type paternal chromosome, where the insulator activity is inhibited by DNA methylation, the enhancers freely interact with the region starting immediately upstream of the DMD. Together, these data suggest that the association between enhancers and promoters does not occur by random collision, but rather by a progressive scanning activity on the part of the enhancers, which then form a stable interaction with the first suitable element they encounter, i.e. the *H19* promoter on the maternal chromosome and the *Igf2* promoter on the paternal chromosome ([@DDN200C27]). The fact that insulators must be located between the enhancer and the promoter supports this model. Strong evidence for this idea is also provided by our *H19*^DMD-9CG^ mutation. The establishment of the insulator on the paternal *H19*^DMD-9CG^ allele seems to act as a roadblock for the enhancers, markedly diminishing their interactions with chromatin lying upstream.

The presence of CTCF at the paternal DMD of the *H19*^DMD-9CG^ allele does not completely block the interaction of the enhancers with the upstream chromatin, although *Igf2* levels are decreased ([@DDN200C10]). This indicates that the insulator established on the methylated DMD is not completely effective in restricting the motility of the enhancers, possibly because of the residual methylation. It also suggests that insulator activity is not all or none, and that there could be varying degrees of enhancer-blocking.

It is striking that in the absence of a blocking activity on the maternal chromosome, the enhancers can both engage the *H19* promoter and also advance beyond it to activate the distal *Igf2* promoter, although whether contacts with both *H19* and *Igf2* occur simultaneously within a single cell is not known. This suggests that, by default, the enhancers are equally capable of activating both promoters. It also implicates that the lack of detectable interactions at *H19* on the wild-type paternal allele is a result of presence of DNA methylation. In fact, when the *H19*^DMD-ΔR^ mutation is transmitted maternally, the *H19* region is hypermethylated and contact with the enhancers is lost. Furthermore, loss of methylation on the paternal *H19* gene in the *H19*^DMD-9CG^ mutation allows the enhancers to access the promoter, again suggesting that the determinant for *H19* silencing and the exclusion of the enhancers is DNA methylation. Thus, our results underscore two roles for paternal DNA methylation as a regulatory switch at this locus. Methylation at the DMD inactivates the insulator by inhibiting CTCF binding. In addition, methylation of the *H19* promoter might neutralize it as a target for enhancer interaction, promoting its bypass in favor of *Igf2*. These results contrast with a previous report that detected enhancer contacts within the *H19* region paternally and concluded that the paternal enhancers have equal access to the whole *H19* and *Igf2* region ([@DDN200C17]). The discrepancy possibly arises from the differences in choice of restriction enzyme. Our restriction digests clearly separate the DMD, the *H19* promoter and the endodermal enhancers into distinct fragments.

The imprinting control region of the *H19*/*Igf2* region is the only vertebrate insulator proven to block enhancer--promoter interactions at the endogenous locus. Two prevailing mechanisms of insulator action have been proposed ([@DDN200C28]--[@DDN200C30]). Topological models propose that insulators are vital for establishing discrete structural loops that restrict the possibility of enhancer--promoter interaction to those elements within the domain. Interaction models assign a regulatory role to insulators, proposing that they compete with the promoter for the enhancer. Previous reports applying 3C technology to the *H19*/*Igf2* locus have led to different models of insulator activity. Kurukuti *et al*. propose a topological model in which the insulator associates with a matrix attachment region and a differentially methylated region at the *Igf2* locus. This would establish a transcriptionally inert loop encompassing the *Igf2* gene. Yoon *et al*. favor a model in which the insulator regulates gene activity by acting as a decoy for the enhancers and the inactive *Igf2* promoter. It is not clear in this model how the enhancers would be available to activate *H19* expression.

Our results support a model in which the enhancers track along the chromosome and engage available promoters. The maternal DMD poses a restriction to this scanning activity, and as a result the enhancers are only present at the *H19* promoter. We propose that rather than acting as a decoy for *Igf2*, CTCF binding to the DMD accomplishes this restriction by acting as a transcriptional facilitator for *H19*. Two lines of evidence support this idea. First, in the absence of CTCF binding sites (*H19*^DMD-ΔR^), initiation of *H19* expression is delayed, clearly implicating CTCF binding in transcriptional activity ([@DDN200C12]). Second, the presence of CTCF binding in the paternal *H19*^DMD-9CG^ correlates with activation of *H19* transcription ([@DDN200C10]).

In conclusion, we present strong evidence that at the *H19*/*Igf2* locus, transcriptional activity is correlated with co-localization of promoters and enhancers. Our data provide new evidence suggesting that the enhancer reaches the target promoter by tracking along the intervening DNA and then looping it out. Our analyses also indicate that the DMD blocks the enhancer from tracking further upstream. One possibility is that the region upstream of the DMD is not accessible to the enhancers because the DMD is in contact with the inactive *Igf2* promoter, as suggested by Yoon *et al*. ([@DDN200C18]) or with the *Igf2* DMR, as reported by Murrell *et al*. ([@DDN200C16]). Either of these interactions leads to the formation of a loop that would exclude the presence of the enhancers. The analyses of our mutations lend support to a different model, in which the enhancers are blocked because CTCF is acting as a transcriptional factor for *H19*. It will be interesting to determine if there are additional proteins involved in insulator activity, as has been reported for cohesins ([@DDN200C31]). Furthermore, it will be exciting to see what factors are involved in the tracking motions of *cis*-acting sequences. For instance, a recent report found that some loci can be recruited to specific nuclear positions in an actin-dependent manner ([@DDN200C32]), and it is tempting to speculate that actin could be involved in enhancer tracking. Ultimately, conformational studies at the human *H19*/*Igf2* locus will be important to gain insight into how loss of imprinting affects the region in disease processes.

MATERIALS AND METHODS {#s4}
=====================

Chromosome conformation capture (3C) {#s4a}
------------------------------------

Livers from newborn mice were homogenized and filtered through a 100 µm nylon cell strainer into 10% FBS/DMEM. Cross-linking with 2% formaldehyde was carried out for 10 min at room temperature and the reaction was quenched with glycine to 0.125 [m]{.smallcaps}. Cells were lysed on ice in lysis buffer (10 m[m]{.smallcaps} Tris pH 8.0, 10 m[m]{.smallcaps} NaCl, 0.2% NP-40 and protease inhibitors). Nuclei were resuspended in restriction buffer containing 0.3% SDS and incubated for 1 h at 37°C. Triton X-100 was added to 1.8% and samples were incubated at 37°C for an additional hour. Digestion with *Psu*I was carried out overnight at 37°C. The reaction was stopped by adding SDS to 2% and incubating at 65°C. An aliquot of the reaction was removed and analyzed and compared with a digest of naked DNA to demonstrate that the digest was complete. DNA was diluted to 2.5 ng/µl with ligase buffer and ligation was carried out on one half of the sample with T4 ligase at 15°C for 4 h. Proteinase K was added to and the samples incubated at 65°C overnight. DNA was purified by phenol extraction and ethanol precipitation.

To create a pool of all possible interacting products, control templates of defined molar amounts were prepared. Control template was prepared from a BAC encompassing the H19/Igf2 region (RP23--50N22, CHORI). The BAC was digested with the appropriate enzymes and ligated. Ligated fragments of interest were amplified by PCR, gel purified and their concentration determined with a Nanodrop spectrophotometer. A mix of equimolar amounts of all the fragments was prepared and used in each reaction. The linear range of amplification was determined for each 3C sample. An amount of DNA within the linear range was used for amplification. All PCR reactions were performed with RubyTaq™ (USB) as follows: 67° 20′′, 72° 20′′ for 15 cycles, with a decrease in the annealing temperature of 2° every 3 cycles, followed by 25 cycles of 55° 20′′, 72° 20′′ and a final extension step of 72° 1′30′′. For all 3C assays, duplicate PCR analyses of two independent 3C preparations were performed. Primer pairs are described in Table [1](#DDN200TB1){ref-type="table"} and their location depicted in Figure [2](#DDN200F2){ref-type="fig"}. PCR products were digested with either *Nla*III or *Hae*III to distinguish the C57BL/6J and B6(CAST7) alleles and run on 12% acrylamide gels.

###### 

Primers used in the 3C assay and the sizes (in base pairs) of the undigested and digested products for each strain

  H19 primers                                            3C product *Nla*III   C57BL/6J   B6(CAST7)
  -------------- --------------------------------------- --------------------- ---------- -----------
  1              GTCTCTGTAGGCCATCACTAAAGAGTATTA          281                   136        281
  2              CATTAGAAGAGAACATTTAGACTCAGACAT          251                   136, 115   251
  3              GTTGCTTTCTGTTTTAGTCAGTGTTCTATT          283                   136, 147   234
  4              CTAGTCCTCAATGTCACGTACTATTACAA           305                   136, 135   170
  5              GTACAATACTACATATTGCTCGGCAGAC            294                   136, 158   294
  6              TTTTCACAGAGTAAAAATGAAGGATCACTA          222                   136        207
  7              ACATAGAAAGGCAGGATAGTTAGCAAAG            350                   136, 214   290
  8              TATGTTTCAGTGACAAGTTAAGGTTGGACAAAG       339                   136, 158   181, 158
  9              GGCAGTAGACCTGACACAGCTTTTCTTC            293                   128        275
  EE/*Nla*III    GTACAGGAGGCTCTACCCCCACCCTCCGTGTG                                         
  Igf2 primers                                                                 *Hae*III   
  10             CAGTGATAACTTTAGATTGTGGATTGTAA           268                   224        185
  11             CCTGTTTTTATATCCTGTACCTCCTAACTA          202                   158        119
  12             CCTCTGCCACCAAGGCCCGAGCCGAGGCCTC         250                   206        167
  13             TGGCTAGAAGGCGAAAGAACGAAAAATGAAG         275                   231        192
  14             CTCGGATTCCAGAAAATGGA                    417                   201, 216   193
  EE/*Hae* III   AAAAGGGACTTCAGACCTTATGCCCCCCACCTACCAG                                    
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